Harmony Biosciences Holdings, Inc.

Harmony Biosciences is a pharmaceutical company focused on developing and commercializing therapies for rare neurological disorders. The company's primary marketed product is WAKIX (pitolisant), a histamine H3-receptor antagonist approved for treating excessive daytime sleepiness in narcolepsy patients. Pitolisant represents the company's core revenue-generating asset and serves as the foundation for its pipeline expansion into other rare neurological indications.

The company's clinical development pipeline includes pitolisant formulations in Phase 3 trials for Prader-Willi Syndrome and Phase 2 studies for myotonic dystrophy, as well as several distinct molecules in development. These include BP1.15205, an orexin 2 receptor agonist; HBS-102, an MCHR1 antagonist; ZYN-002, in Phase 3 testing for Fragile X Syndrome and 22q deletion syndrome; and various in-licensed assets such as EPX-100 and EPX-200 for epilepsy indications, and CBS105 and CBS104 for narcolepsy and refractory epilepsy respectively.

Harmony Biosciences operates with approximately 293 full-time employees and maintains headquarters in Plymouth Meeting, Pennsylvania. The company was incorporated in Delaware in 2017 and is listed on Nasdaq. Its commercial operations are currently limited to the United States market, though its pipeline spans multiple rare neurological disease areas with significant unmet medical needs.